Therapy News and Research

RSS

Triamcinolone may be a treatment option for some patients with retinal vein occlusion

Injecting the eye with the corticosteroid triamcinolone appears effective in improving the vision of some patients with retinal vein occlusion, an important cause of vision loss that results from blockages in the blood vessels in the retina, according to two reports in the September issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

15 Sep 2009

Phase III results of Lauriad presented at the 49th Annual ICAAC

BioAlliance Pharma has attended the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco to present results on miconazole Lauriad and anti-integrase inhibitor.

15 Sep 2009

Phase II VICTOR-E1 clinical study results reported

Schering-Plough Corporation today reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients.

15 Sep 2009

miR-200 supression shifts primary lung cancer to metastatic disease

Primary lung cancer shifts to metastatic disease by suppressing a family of small molecules that normally locks the tumor in a noninvasive state, researchers at The University of Texas M. D. Anderson Cancer Center report in the Sept. 15 edition of Genes and Development.

15 Sep 2009

HFSA's annual scientific meeting features four late breaking clinical trials

The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured four late breaking clinical trials at the Hynes Convention Center in Boston.

15 Sep 2009

Stimulating effect of bioactive collagen peptides in cell experiments demonstrated

Working in collaboration with Kiel University, researchers at the Kiel- based Collagen Research Institute (CRI) have demonstrated the stimulating effect of special bioactive collagen peptides (FORTIGEL(R)) in the context of cell experiments. Last weekend the CRI presented its research findings at the congress of the Osteoarthritis Research Society International (OARSI) in Montreal.

15 Sep 2009

HFSA's 13th Annual Scientific Meeting focuses on causes and treatment of heart failure

The Heart Failure Society of America's (HFSA) 13th Annual Scientific Meeting convened Sunday, September 13, 2009 at the Hynes Convention Center in Boston. This three-day meeting -- a forum for heart failure specialists to present research findings and advances in treatment -- will address emerging trends in research and new developments in the approach to treating patients with this condition.

15 Sep 2009

Excessive physical strain in dementia care linked to communication problems

Excessive physical strain in dementia care is not so much related to equipment or the resident's body weight as it is due to communication problems and misunderstandings. This is shown in a new study from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

15 Sep 2009

Elsevier launches new web platform

Elsevier, the leading publisher of scientific, technical and medical information products and services, announced today the launch of a new web platform, Elsevier Mental Health (www.elseviermentalhealth.com).

15 Sep 2009

Study reveals that daily bathroom showers may deliver pathogenic bacteria

While daily bathroom showers provide invigorating relief and a good cleansing for millions of Americans, they also can deliver a face full of potentially pathogenic bacteria, according to a surprising new University of Colorado at Boulder study.

15 Sep 2009

Common pain cream could serve as cardiac-protectant during heart attack: Study

New research from the University of Cincinnati (UC) shows that a common, over-the-counter pain salve rubbed on the skin during a heart attack could serve as a cardiac-protectant, preventing or reducing damage to the heart while interventions are administered.

15 Sep 2009

BioAlliance announces Phase III results of miconazole Lauriad MBT for treatment of oropharyngeal candidiasis

Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that its development partner BioAlliance Pharma SA presented Phase III study results for miconazole Lauriad(R) mucoadhesive buccal tablets (MBT) that demonstrate noninferiority to clotrimazole troches for oropharyngeal candidiasis (OPC), an opportunistic infection of the mouth and throat.

14 Sep 2009

Boston Software and Vocollect collaborate to seamlessly integrate AccuNurse with MEDITECH

Vocollect, Inc., the global leader in voice technology and Boston Software Systems, the leader in workflow automation to the healthcare market, today announced a strategic partnership.

14 Sep 2009

Phase 1 trial results of Achaogen's ACHN-490 announced at ICAAC meeting

Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug candidate ACHN-490 at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting in San Francisco, CA.

14 Sep 2009

Diabetes drug and chemotherapy kill cancer stem cells in mice

In a one-two punch, a familiar diabetes drug reduced tumors faster and prolonged remission in mice longer than chemotherapy alone by targeting cancer stem cells, Harvard Medical School researchers reported in the September 14 online first edition of Cancer Research, a journal of the American Association for Cancer Research.

14 Sep 2009

Clinical studies reveal treatment with pirfenidone is safe and well-tolerated

InterMune, Inc. (Nasdaq: ITMN) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, Germany.

14 Sep 2009

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.

14 Sep 2009

New data confirm link between Epstein-Barr virus and multiple sclerosis

Over the last 40 years, Epstein-Barr virus (EBV) has been repeatedly associated with multiple sclerosis and other autoimmune diseases. During the 2nd European Congress of Immunology ECI 2009 held in Berlin, Francesca Aloisi, Istituto Superiore di Sanità, Rome, will present new data that further support the link. In the brain lesions of patients with multiple sclerosis her team found abnormal accumulation of EBV infected B lymphocytes.

14 Sep 2009

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced the initiation of a dose escalation study with its oncology drug candidate tamibarotene combined with TRISENOX® (arsenic trioxide) injection (marketed by Cephalon, Inc.) in patients with relapsed acute promyelocytic leukemia (APL).

14 Sep 2009

Calypso’s GPS for the Body technology installed at University Of Maryland Greenebaum Cancer Center

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, announced today that the University of Maryland Marlene and Stewart Greenebaum Cancer Center, a National Cancer Institute-designated cancer center in Baltimore, now offers the Calypso® System to provide accurate, precise, real-time tumor tracking for cancer patients undergoing external beam radiation therapy.

14 Sep 2009

Therapy News and Research

Triamcinolone may be a treatment option for some patients with retinal vein occlusion

Phase III results of Lauriad presented at the 49th Annual ICAAC

Phase II VICTOR-E1 clinical study results reported

miR-200 supression shifts primary lung cancer to metastatic disease

HFSA's annual scientific meeting features four late breaking clinical trials

Stimulating effect of bioactive collagen peptides in cell experiments demonstrated

HFSA's 13th Annual Scientific Meeting focuses on causes and treatment of heart failure

Excessive physical strain in dementia care linked to communication problems

Elsevier launches new web platform

Study reveals that daily bathroom showers may deliver pathogenic bacteria

Common pain cream could serve as cardiac-protectant during heart attack: Study

BioAlliance announces Phase III results of miconazole Lauriad MBT for treatment of oropharyngeal candidiasis

Boston Software and Vocollect collaborate to seamlessly integrate AccuNurse with MEDITECH

Phase 1 trial results of Achaogen's ACHN-490 announced at ICAAC meeting

Diabetes drug and chemotherapy kill cancer stem cells in mice

Clinical studies reveal treatment with pirfenidone is safe and well-tolerated

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

New data confirm link between Epstein-Barr virus and multiple sclerosis

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

Calypso’s GPS for the Body technology installed at University Of Maryland Greenebaum Cancer Center

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News